App-Quantinova.ai

Home Blood Pressure Monitoring Among Us Adults Without Hypertension: How Do Existing Patient and Physician Behaviors Correspond to Current Recommendations?

Kelsey B Bryant - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Renal disease

N/A

Myocardial Deformation Analysis in Hypertrophic Cardiomyopathy With Sarcomere Mutations: Insights From 2,221 Patients Within the NHLBI-HCM Registry

Bobak Heydari - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Hypertrophic cardiomyopathy

N/A

Adverse Right Ventricular Remodelling, Function and Stress Responses in Obesity: Implications for Severe Acute Respiratory Illness

Andrew J Lewis - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Myocardial Ischaemia in Cardiac Amyloidosis, Changing Perspectives

Liza Chacko - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Cardiac amyloidosis

Adenosine

A Novel CT-derived Radiotranscriptomic Signature of Perivascular Adipose Tissue Stratifies COVID-19 Vascular Cytokine Burst and Predicts in Hospital Outcomes

Christos P Kotanidis - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Effect of Severe Anemia (hemoglobin < 10g/dl) on Short- and Long-term Outcome in Acute Coronary Syndrome: Insights of a Terciary Centre

Isabel Campos - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Acute Coronary Syndromes

N/A

Efficacy and Safety of Bempedoic Acid in Patients Who Cannot Tolerate Statins: Pooled Analysis of 4 Phase 3 Clinical Trials

Ulrich Laufs - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Short stature, auditory canal atresia, mandibular hypoplasia, skeletal abnormalities

ESP55016

In-Hospital Outcomes of Coronary Artery Bypass Grafting Candidates Undergoing Percutaneous Coronary Intervention During the Intensive Care Unit Restricted Covid-19 Pandemic: The Multi-Centre Prospective UK-REVASC Registry

Thomas A Kite - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

Desirudin

Exercise Capacity as a Predictor of the Placebo-controlled Efficacy of Percutaneous Coronary Intervention in Stable Coronary Artery Disease: The Ventilatory Gas Exchange-stratified Analysis of ORBITA

Sashiananthan Ganesananthan - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Stable coronary artery disease

N/A

Reduction in the Risk of Major Adverse Cardiovascular Events With Apabetalone, a Bet Protein Inhibitor, in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes According to Insulin Treatment: Analysis of the Betonmace Trial

Gregory G Schwartz - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Acute Coronary Syndromes

RVX-208

Effects of Intensive Smoking Cessation Counseling After Acute Coronary Syndrome on 5-year Incidence of Major Adverse Cardiovascular Events and Smoking Abstinence

Lauriane Gilgien Denereaz - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Acute Coronary Syndromes

N/A

Relationship Between Baseline Low-Density Lipoprotein Cholesterol and Percent Low-Density Lipoprotein Cholesterol Reduction With Evolocumab in the FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk) Trial

Dan P Marcusa - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

Evolocumab

Relative Efficacy of Alirocumab, Bempedoic Acid, Evolocumab, Ezetimibe and Inclisiran Added to Statins for Reduction of Low Density Lipoprotein Cholesterol - A Network Meta-Analysis of Randomized Clinical Trials

Peter P Toth - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

ESP55016

Does Yoga Based Cardiac Rehabilitation (Yoga-CaRe) Programme Improve Endothelial Function and Reduce Oxidative Stress in Patients With Acute Myocardial Infarction?

Satish G Patil - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Myocardial infarction

Superoxide dismutase

Prevalence, Trends and Impact of Cannabis Use on Hospitalizations With Prior Myocardial Infarction and Revascularization

Rupak Desai - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Myocardial infarction

N/A

Ventilatory Gas Exchange in Stable Coronary Artery Disease

Sashiananthan Ganesananthan - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Stable coronary artery disease

Dobutamine

Effect of COVID-19 Public Health Measures on Activity and Quality of Life in Patients With Pulmonary Arterial Hypertension

Jennifer T Middleton - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Pulmonary arterial hypertension

N/A

Lifetime Benefit of Empagliflozin in Extending Survival Free From Insulin Initiation in Type 2 Diabetes and Cardiovascular Disease: An Actuarial Analysis of EMPA-REG OUTCOME

Muthiah Vaduganathan - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Type 2 diabetes mellitus

BI-10773

Effect of Empagliflozin on Total Events of Myocardial Infarctions by Subtype in the EMPA-REG OUTCOME Trial

David H Fitchett - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

BI-10773

Inhibition of Egfr Signalling Promotes Maladaptive Cardiac Remodelling in Hypertensive Heart Disease

Susanna Cooper - American Heart Association (AHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hypertensive heart disease

Angiotensin II

Filters

45280 Abstracts